Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.
Vick-Fragoso R, Hernández-Oliva G, Cruz-Alcázar J, Amábile-Cuevas CF, Arvis P, Reimnitz P, Bogner JR; STIC Study Group. Vick-Fragoso R, et al. Among authors: reimnitz p. Infection. 2009 Oct;37(5):407-17. doi: 10.1007/s15010-009-8468-x. Epub 2009 Sep 18. Infection. 2009. PMID: 19768381 Clinical Trial.
Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.
Schaper NC, Dryden M, Kujath P, Nathwani D, Arvis P, Reimnitz P, Alder J, Gyssens IC. Schaper NC, et al. Among authors: reimnitz p. Infection. 2013 Feb;41(1):175-86. doi: 10.1007/s15010-012-0367-x. Epub 2012 Nov 23. Infection. 2013. PMID: 23180507 Free PMC article. Clinical Trial.
A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.
Gyssens IC, Dryden M, Kujath P, Nathwani D, Schaper N, Hampel B, Reimnitz P, Alder J, Arvis P. Gyssens IC, et al. Among authors: reimnitz p. J Antimicrob Chemother. 2011 Nov;66(11):2632-42. doi: 10.1093/jac/dkr344. Epub 2011 Sep 6. J Antimicrob Chemother. 2011. PMID: 21896561 Free PMC article. Clinical Trial.
Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.
Ross JD, Cronjé HS, Paszkowski T, Rakoczi I, Vildaite D, Kureishi A, Alefelder M, Arvis P, Reimnitz P; MAIDEN Study Group. Ross JD, et al. Among authors: reimnitz p. Sex Transm Infect. 2006 Dec;82(6):446-51. doi: 10.1136/sti.2005.019109. Epub 2006 May 24. Sex Transm Infect. 2006. PMID: 16723364 Free PMC article. Clinical Trial.
Comparison of the efficacy and safety of faropenem daloxate and cefuroxime axetil for the treatment of acute bacterial maxillary sinusitis in adults.
Siegert R, Berg O, Gehanno P, Leiberman A, Martinkenas JL, Nikolaidis P, Arvis P, Alefelder M, Reimnitz P. Siegert R, et al. Among authors: reimnitz p. Eur Arch Otorhinolaryngol. 2003 Apr;260(4):186-94. doi: 10.1007/s00405-002-0532-4. Epub 2002 Oct 11. Eur Arch Otorhinolaryngol. 2003. PMID: 12709801 Clinical Trial.
Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.
Welte T, Petermann W, Schürmann D, Bauer TT, Reimnitz P; MOXIRAPID Study Group. Welte T, et al. Among authors: reimnitz p. Clin Infect Dis. 2005 Dec 15;41(12):1697-705. doi: 10.1086/498149. Epub 2005 Nov 10. Clin Infect Dis. 2005. PMID: 16288390 Clinical Trial.
27 results